Rumors of an imminent acquisition of Alexion Pharmaceuticals sent the stock jumping, and while a that may not pan out, SVB Leerink thinks a more-concrete deal may be in the drug maker’s future.
Rumors of an imminent acquisition of Alexion Pharmaceuticals sent the stock jumping, and while a that may not pan out, SVB Leerink thinks a more-concrete deal may be in the drug maker’s future.